| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System |
Recent Updates
Recently added Catalysts
Xencor, Inc.$14.98
+0.03 (+0.2%)
C 45Pipeline Score Fair Value Biotech · Clinical
Market Cap
838.54 M
EPS
-2.30
P/E Ratio
-
Value Trade
6.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
4.52 M
R&D Expenses
64.67 M
Operating CF
-67.63 M
Total Assets
736.85 M
Total Liabilities
221.21 M
Equity
515.63 M
D/E Ratio
12,345
-3 %
Week
-10.87 %
1 Month
-4.15 %
3 Month
-27.55 %
6 Month
-72.6 %
5 Year
90.08 %
All Time
Cash Data
Cash Position
548.61 M
Monthly Burn
22.54 M
Runway
22.1 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
487.45 K
52 Week Range
6.92 - 18.69
% held by Insiders
5.89 %
% held by Institutions
110.05 %
Enterprise Value
568.76 M
Total Shares
74.14 M
Short %
16.49 %
Float Shares
74.14 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xencor, Inc.
514Total events
10Upcoming
122Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
▲First Patient DosedXmAb412Trial
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C45
Pipeline Score $761M
Pipeline ValueFair Value
Valuation Signal18
Drugs Scored0.9x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 912)
Percentile RankXencor, Inc. carries a moderate pipeline score (45/100), with $2.6B risk-adjusted pipeline value, led by XmAb5871 in IgG4-RD (Phase 2), across $121B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XmAb5871 Monoclonal antibody | IgG4-RD | Phase 2 | NCT02725476 | 26% | $704M | COMPLETED | 20 | - | - | Dec 1, 2017 | - | Dec 7, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
XmAb819 | advanced clear cell renal cell carcinoma | Phase 1 | 2025-10-24 | promising early signs of efficacy and safety with administered doses Read More | xncr-2025x1024xexx991 Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update Read More | |
XmAb819 | advanced clear cell renal cell carcinoma | Phase 1 | 2025-10-24 | promising early signs of efficacy and safety with administered doses Read More | xncr-2025x1024xexx991 Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update Read More | |
XmAb819 | advanced clear cell renal cell carcinoma | Phase 1 | 2025-10-24 | promising early signs of efficacy and safety with administered doses Read More | xncr-2025x1024xexx991 Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XNCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XNCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XNCRXencor Reports First Quarter 2026 Financial Results
Xencor has reported its financial results for the first quarter of 2026. The article does not provide specific details about the financial performance or any significant developments during this period. Further insights into the company's operations or future outlook are not mentioned.
Read more →XNCRxncr-20260504xexx991 Designing Proteins Delivering Medicines Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update
Xencor has reported positive results from its Phase 1 study of XmAb942, a drug targeting TL1A for inflammatory bowel disease. The company highlighted its strong financial foundation and innovative protein engineering capabilities during a recent presentation. XmAb942 is part of a broader portfolio aimed at addressing conditions such as ulcerative colitis. Despite the optimistic results, Xencor acknowledged potential risks related to development timelines and dependence on third parties.
Read more →XNCR▲ +5.3%on this newsshared move
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor is set to host a webcast to discuss data presentations for XmAb942 and XmAb412 at the upcoming Digestive Disease Week (DDW). This event will provide insights into the latest findings related to these compounds. Further details about the webcast and its content were not disclosed.
Read more →XNCR▼ -12.4%on this news
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
Xencor, Inc. announced that Alexion Pharmaceuticals has stated it will not pay additional royalties for Ultomiris sales in the U.S. while continuing payments for international sales. This dispute has led Xencor to adjust its financial guidance, projecting sufficient cash resources into mid-2028 despite the uncertainty regarding U.S. royalties. The company remains focused on resolving the matter with the Licensee.
Read more →XNCR▲ +13.1%on this news
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Xencor reported its financial results for Q4 and the full year 2025, highlighting the progress of its clinical pipeline, particularly XmAb819 for ccRCC. The company is on track to present data supporting a Phase 3 dose in 2026 and has opened new cohorts for other cancers. Despite a net loss, revenue increased due to licensing agreements, and cash reserves remain strong.
Read more →XNCRXencor to Participate at Upcoming March 2026 Investor Conferences
Xencor, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company, which focuses on developing engineered antibodies for cancer and autoimmune diseases, will provide live webcasts of the presentations. Replays will be available on their website for 30 days post-event.
Read more →XNCR▼ -5.1%on this news
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones PASADENA, Calif.
Xencor, Inc., a clinical-stage biopharmaceutical company, has outlined its corporate priorities and key pipeline advancements for 2026, focusing on its XmAb drug candidates for cancer and autoimmune diseases. They plan to initiate pivotal studies and first-in-human trials for several innovative therapies, including bispecific antibodies targeting important inflammatory pathways. Recent clinical data from its XmAb819 candidate shows promise in advanced renal cell carcinoma, contributing to a robust development strategy supported by a strong financial position expected to last through 2028. The company anticipates presenting important updates and milestones across their clinical programs in the coming year.
Read more →XNCRXencor Reports Third Quarter 2025 Financial Results PASADENA, Calif.
Xencor, Inc. reported its financial results for Q3 2025, highlighting advancements in its bispecific antibodies, XmAb819 and XmAb541, which are in Phase 1 studies for cancer treatment. Both candidates showed encouraging clinical data, and Xencor expects to initiate pivotal studies in 2027. Additionally, the company is progressing in its autoimmune portfolio, with patient dosing underway for XmAb942 and plamotamab. Xencor's financial health appears robust, with expectations to sustain operations into 2028.
Read more →XNCR▲ +7.1%on this news· ran to +19% by day 3
xncr-2025x1024xexx991 Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update
Xencor has released initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a T-cell engager targeting ENPP3 for advanced clear cell renal cell carcinoma. The trial demonstrates promising early signs of efficacy and safety with administered doses. Additionally, the pharmacokinetic data suggest that the drug may support a more convenient dosing schedule. While there are optimistic findings, it is important to consider the risks involved, particularly the heavily pre-treated nature of the patient population. Xencor continues to advance its oncology pipeline, highlighting its ongoing commitment to innovative cancer therapies.
Read more →XNCR▼ -5.8%on this news
Xencor Reports Second Quarter 2025 Financial Results PASADENA, Calif.
Xencor, Inc. has reported its financial results for the second quarter of 2025, showing a significant revenue increase to $43.6 million. The company is advancing multiple clinical studies with promising drug candidates such as XmAb819 and XmAb942 in the oncology and autoimmune disease spaces. Despite the positive growth, Xencor faced a net loss of $30.8 million, although this represents an improvement from the previous year's loss. The firm continues to invest heavily in R&D while preparing for upcoming pivotal trials.
Read more →XNCRinvestigational," "indicates," "supports," and similar terms, or by express or implied discussions relating to Xencor's business, including but not limited to, the quotations from Xencor's president and chief executive o
Xencor, Inc. has appointed Raymond J. Deshaies, Ph.D., to its board of directors, bringing over 25 years of experience in biotechnology. Dr. Deshaies has a notable background, having recently served as senior vice president of global research at Amgen, where he oversaw numerous successful clinical candidates. His expertise in drug development and scientific insights is expected to enhance Xencor's advancements in engineered antibodies targeting cancer and autoimmune diseases.
Read more →XNCR▼ -5.6%on this news
Xencor Reports First Quarter 2025 Financial Results -- Recent interim Phase 1 study results for XmAb942 (Xtend anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with
Xencor, Inc. reported its financial results for the first quarter of 2025, highlighting promising interim results for its investigational drug XmAb942, which supports a 12-week maintenance dosing regimen for ulcerative colitis. The company is poised to initiate a Phase 2b study, named XENITH-UC, in the latter half of 2025. Additionally, Xencor announced personnel changes as Nancy Valente transitions from Chief Development Officer to a senior advisory role. The firm has also provided guidance for its financial outlook and expects to maintain sufficient cash flow into 2028.
Read more →XNCRxncr-20250429xexx991 Interim Results from First-in-Human Study of XmAb942 & TL1A Pipeline Update
Xencor recently provided interim results from the first-in-human study of XmAb942, an antibody designed for treating inflammatory bowel disease (IBD). The company is also advancing multiple clinical candidates, including various bispecific T-cell engagers targeting cancer and autoimmune conditions. XmAb942 is characterized by an extended half-life, aiming to enhance patient compliance with its convenient dosing schedule. However, Xencor acknowledges the inherent risks associated with moving forward in clinical development timelines.
Read more →XNCRXencor Appoints Todd Simpson to Board of Directors PASADENA, Calif.
Xencor, Inc. has appointed Todd Simpson to its board of directors. Simpson, a seasoned financial executive with over 40 years of experience, previously served as CFO at Seagen Inc. where he was instrumental in the launch of multiple oncology medicines. His extensive background in corporate finance and strategic planning is expected to benefit Xencor as it continues to develop engineered antibodies for cancer and autoimmune diseases.
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2024 Financial Results PASADENA, Calif.--(BUSINESS WIRE)
Xencor, Inc. reported its fourth quarter and full year 2024 financial results, highlighting a rebalancing of its pipeline to prioritize XmAb drug candidates. The company is optimistic about its oncology portfolio and plans to present significant data on its leading candidates in 2025. Financial results showed a slight revenue increase for Q4 2024 compared to Q4 2023, although total revenue for the year declined. Xencor maintains strong cash reserves, projected to support operations through 2028.
Read more →XNCR▲ +5.4%on this news
Xencor Reports Third Quarter 2024 Financial Results PASADENA, Calif
Xencor, Inc. reported its financial results for Q3 2024, highlighting a significant drop in revenue to $10.7 million. Despite this, the company announced positive advancements in its clinical pipeline, particularly with XmAb942 entering Phase 1 studies. Additionally, Xencor raised $201.3 million through a public offering to support its ongoing projects, though it noted an increase in R&D expenses for continued program development. The report also mentioned mixed clinical outcomes, including some patients experiencing serious side effects during trials.
Read more →XNCRXencor Announces Upcoming Change to Board of Directors PASADENA, Calif.
Xencor, Inc. announced that Dagmar Rosa-Bjorkeson will not seek reelection to its Board of Directors during the 2025 Annual Meeting. Rosa-Bjorkeson has been a board member since 2019 and plans to pursue another business opportunity. The company is actively seeking additional board members with complementary skills. Xencor continues to focus on advancing its clinical-stage biopharmaceutical pipeline, which includes engineered antibodies for cancer and serious diseases.
Read more →XNCRDocument Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Xencor, a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, raising about $201.3 million. The offering included 8,093,712 shares of common stock at a price of $18.00 each, and underwriters fully exercised their option for additional shares. The company intends to use the proceeds for various corporate purposes, including research and development. This development is part of Xencor's ongoing efforts to advance its pipeline of engineered antibody therapies for cancer and other serious diseases.
Read more →XNCRXencor Announces Proposed Public Offering of Common Stock
Xencor, Inc. has announced a proposed public offering of its common stock to raise funds for general corporate purposes, including research and development. The company is offering shares along with an option for certain investors to acquire pre-funded warrants. Underwriters have a 30-day option to purchase additional shares, but the offering remains subject to market conditions and lacks assurance of completion. Xencor aims to utilize the proceeds to further its clinical-stage pipeline, which includes over 20 candidates in development.
Read more →XNCR▲ +22.9%on this newsshared move
Document Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs -- Phase 1 healthy volunteer study of half-life extended an
Xencor has announced advancements in its drug development pipeline, focusing on autoimmune diseases and early-stage oncology programs. Notably, its XmAb819 drug candidate is showing promising initial clinical activity in treating advanced renal cell carcinoma. The company is set to initiate several clinical studies, including a notable trial for the half-life extended anti-TL1A antibody XmAb942 aimed at inflammatory bowel diseases, with dosing expected to start in Q4 2024. Xencor maintains an optimistic outlook for significant milestones ahead.
Read more →XNCR▼ -7.3%on this news
Xencor Reports Second Quarter 2024 Financial Results
Xencor, Inc. reported its financial results for Q2 2024, highlighting advancements in its bispecific T-cell engagers and an optimistic clinical pipeline. The company noted a significant decrease in revenue year-over-year, primarily due to changes in revenue sources. Additionally, Xencor faces challenges with a notable net loss compared to the same quarter in 2023. Despite these financial hurdles, the company anticipates advances in its clinical-stage programs and remains confident in its research and development goals.
Read more →XNCRXencor Regains CD20 x CD3 Bispecific T-Cell Engager PASADENA, Calif.
Xencor, Inc. has announced that it will regain exclusive worldwide rights to plamotamab, a bispecific T-cell engager developed for treating hematologic cancers. This decision comes after Janssen Biotech has opted to terminate its rights under a previous collaboration agreement. Xencor, which completed enrollment in a Phase 1 study of plamotamab in late 2023, aims to evaluate its potential to address unmet medical needs as it prepares for Phase 2 trials. The company continues to collaborate with Janssen on two other CD28-targeting bispecific antibodies.
Read more →XNCRXencor Reports First Quarter 2024 Financial Results
Xencor, Inc. has reported its financial results for Q1 2024, showcasing a revenue decline and an increased net loss compared to the prior year. Despite these financial challenges, the company is advancing its pipeline of bispecific T cell engagers in clinical trials. Notably, the FDA has approved Ultomiris, which uses Xencor's Xtend technology, for treating NMOSD, underlining the commercial viability of its innovations. Furthermore, promising results from a malaria prevention study highlight the effectiveness of its investigational antibody.
Read more →XNCRstatements of historical fact, and can generally be identified by the use of words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committe
Xencor, Inc. has announced the appointment of Bart Cornelissen as its new Chief Financial Officer. Cornelissen brings over two decades of experience in corporate finance, having recently served as vice president at Seagen Inc. He is expected to play a key role in advancing Xencor's pipeline of engineered antibodies aimed at treating cancer and other serious diseases. Xencor has established itself as a leader in protein engineering and continues to develop innovative therapeutics alongside commercialization efforts.
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. has announced its financial results for Q4 and the full year 2023, reporting a revenue increase primarily driven by collaborations with Janssen Biotech. The company is advancing its clinical development focusing on XmAb T-cell engagers and the dual checkpoint inhibitor, vudalimab, which displayed promising early results in treating high-risk metastatic castration-resistant prostate cancer. Though the company is optimistic about its pipeline, a workforce reduction of approximately 10% and a serious adverse event were noted.
Read more →XNCRXencor Sells Portion of Royalties and Milestones from Ultomiris and Monjuvi to OMERS Life Sciences for $215 Million
Xencor, a clinical-stage biopharmaceutical company, has sold portions of its financial interests in Ultomiris and Monjuvi to OMERS Life Sciences for $215 million. This agreement allows OMERS to acquire royalties from global sales of Ultomiris and Monjuvi, while Xencor benefits from immediate capital and retains potential future payments. The company's leader emphasized that this financial boost will enhance their ability to pursue internal clinical development projects.
Read more →XNCRXencor Reports Third Quarter 2023 Financial Results -- Royalty Transaction Generates $215 Million Upfront -- -- Management to Host Conference Call at 4 30 p.m. ET Today -- PASADENA, Calif.
Xencor, Inc. reported its Q3 2023 financial results, highlighting a significant royalty transaction with OMERS Life Sciences that generated $215 million upfront. The company’s financial results showed increased revenues driven by milestone and royalty payments. However, Xencor announced the cessation of its XmAb104 development program and limited enrollment in ongoing studies due to emerging competitive challenges. The company aims to focus on more promising bispecific antibody programs going forward.
Read more →XNCRXencor Announces Planned Retirement of Chief Financial Officer John Kuch PASADENA, Calif.
Xencor, Inc. has announced the planned retirement of Chief Financial Officer John Kuch in March 2024, ending a 23-year tenure at the company. Kuch has played a pivotal role in Xencor's financial success and development as a clinical-stage biopharmaceutical firm. He will assist in the search for his successor and continue with a consulting arrangement post-retirement. The transition marks a significant moment for Xencor as it continues to advance its innovative technologies and pipeline of treatments for cancer and autoimmune diseases.
Read more →XNCRXencor Appoints Barbara J.
Xencor, Inc. has appointed Dr. Barbara J. Klencke to its board of directors. Dr. Klencke brings extensive experience in biopharmaceutical product development, having previously served as CMO at Sierra Oncology, where she oversaw the approval of Ojjaara for myelofibrosis. Her background also includes key roles at Onyx Pharmaceuticals and Genentech, contributing to the success of multiple cancer treatments. Xencor aims to leverage her expertise as they advance their pipeline of engineered antibodies and cytokines for cancer and autoimmune diseases.
Read more →XNCRXencor Reports Second Quarter 2023 Financial Results -- Management to Host Conference Call at 4 30 p.m. ET Today -- PASADENA, Calif.
Xencor, Inc. has reported its financial results for the second quarter of 2023, highlighting progress in its clinical portfolio and a significant increase in revenue. The company plans to initiate a Phase 2 study for vudalimab in non-small cell lung cancer by year-end, which is a promising development for patients with high unmet needs. Despite experiencing a net loss, the company maintains a strong cash position to fund operations through 2025 and continues to expand its range of drug candidates.
Read more →XNCRXencor Reports First Quarter 2023 Financial Results -- Management to Host Conference Call at 4 30 p.m. ET Today -- PASADENA, Calif.
Xencor, Inc. reported its financial results for the first quarter of 2023, highlighting ongoing patient enrollment in various clinical studies for its XmAb drug candidates. The company is advancing two new programs into clinical development within the year. However, financial performance showed a significant drop in revenue compared to the previous year, alongside a net loss, primarily due to decreased royalties. Despite these challenges, Xencor continues to make progress with its drug pipeline and has bolstered its executive team.
Read more →XNCRXencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, Inc. announced the appointment of Nancy Valente, M.D., as Chief Development Officer, effective May 1, 2023. Dr. Valente, who has over 20 years of experience in biopharmaceutical development, previously served as senior vice president at Genentech. She will lead Xencor's clinical and medical strategy while transitioning from her role on the Board of Directors. Xencor's management expressed confidence in Dr. Valente's ability to enhance the company's drug development and strategic initiatives.
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2022 Financial Results
Xencor, Inc. has announced its financial results for Q4 and the full year ending December 31, 2022. The company continues to advance its pipeline, including notable Phase 2 studies and ongoing trials for various drug candidates aimed at cancer and autoimmune diseases. Despite a decrease in revenue year-over-year, Xencor maintains a robust cash position and has formed several strategic partnerships to support its future development initiatives.
Read more →XNCRXencor Reports Third Quarter 2022 Financial Results -- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study
Xencor Reports Third Quarter 2022 Financial Results -- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study -- -- Management to host conference call at 4:30 p.m. ET
Read more →XNCRXencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor s XmAb
Xencor Appoints Nancy Valente, M.D., to Board of Directors MONROVIA, Calif.--September 9, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today annou
Read more →XNCRXencor Reports Second Quarter 2022 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports Second Quarter 2022 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 3, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the t
Read more →XNCRXencor Reports First Quarter 2022 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports First Quarter 2022 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--May 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treat
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--Feb. 23, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki
Read more →XNCRXencor Reports Thirds Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 -- Management to Host Conference Call at 4:30 p.m. E
Xencor Reports Thirds Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--Nov. 8, 2021-- Xencor, Inc. (
Read more →XNCR▲ +5.5%on this news
Xencor Enters Global Collaboration and License Agreement with Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients with B-Cell Malignancies -- Second agreement with J
Xencor Enters Global Collaboration and License Agreement with Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients with B-Cell Malignancies -- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co
Read more →XNCRXencor Reports Second Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports Second Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokine
Read more →XNCRXencor Reports First Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports First Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--May 5, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines fo
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--Feb. 23, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies
Read more →XNCRXencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer -- Research collaboration focused on the discovery of novel bispecific antibodies direct
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer -- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclos
Read more →XNCRXencor Reports Third Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. EST Today -- MONROVIA, Calif.
Xencor Reports Third Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. EST Today -- MONROVIA, Calif.--Nov. 5, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatm
Read more →XNCRPreliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors Background XmAb20717 is a humanized bispecific monoc
Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors XmAb20717 is a humanized bispecific monoclonal antibody that simultaneously targets PD-1 and CTLA-4. We report
Read more →XNCRXencor Reports Second Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.
Xencor Reports Second Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 4, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the trea
Read more →XNCRXencor Reports First Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today
Xencor Reports First Quarter 2020 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif., May 7, 2020 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatme
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif., Feb. 24, 2020 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodie
Read more →XNCRXencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors MONROVIA, Calif.
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors MONROVIA, Calif.--Dec. 20, 2019 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic
Read more →XNCRXencor Reports Third Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif.
Xencor Reports Third Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif.--Nov. 5, 2019--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatme
Read more →XNCRXencor Reports Second Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif.
Xencor Reports Second Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif.--August 6, 2019--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the trea
Read more →XNCRXencor Reports First Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today
Xencor Reports First Quarter 2019 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif., May 9, 2019 -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatm
Read more →XNCRXencor Announces Closing of Research Collaboration and License Agreement with Genentech
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech MONROVIA, Calif., Mar. 8, 2019 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asth
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2018 Financial Results - Initial Data from Phase 1 Study of XmAb 14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results - Initial Data from Phase 1 Study of XmAb 14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA - - Res
Read more →XNCRXencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Comm
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Commercialized Medicines MONROVIA, Calif., February 5, 2019 Xe
Read more →XNCRXencor Appoints Ellen G. Feigal, M.D., to Board of Directors
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors MONROVIA, Calif., November 8, 2018 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseas
Read more →XNCRXencor Reports Third Quarter 2018 Financial Results - Initial Data from Phase 1 Dose-Escalation Study of XmAb 14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3
Xencor Reports Third Quarter 2018 Financial Results - Initial Data from Phase 1 Dose-Escalation Study of XmAb 14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3 Study of XmAb 5871 in IgG4-Related Disease (IgG4-RD) by Ea
Read more →XNCRXencor Reports Second Quarter 2018 Financial Results Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb 20717 in Advanced Solid Tumors Expect to Announce Topline
Xencor Reports Second Quarter 2018 Financial Results Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb 20717 in Advanced Solid Tumors Expect to Announce Topline Data from Phase 2 Trial of XmAb 5871 in Systemic Lupus Er
Read more →XNCRXencor Reports First Quarter 2018 Financial Results Introduced XmAb IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb 24306 at American Association for Cancer Research (AACR) Annual Meeting Complet
Xencor Reports First Quarter 2018 Financial Results Introduced XmAb IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb 24306 at American Association for Cancer Research (AACR) Annual Meeting Completed Public Offering, Raising $245.5M and Extending Cash Run
Read more →XNCRXencor, Inc. Announces Proposed Public Offering of Common Stock
Xencor, Inc. Announces Proposed Public Offering of Common Stock MONROVIA, Calif., March 19, 2018 Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2017 Financial Results Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb 24306, Targeting IL-15/ILR for Multiple Oncology Indications Expect to In
Xencor Reports Fourth Quarter and Full Year 2017 Financial Results Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb 24306, Targeting IL-15/ILR for Multiple Oncology Indications Expect to Initiate Phase 3 Trial of XmAb 5871 in IgG4-Related Disease
Read more →XNCRXencor Appoints Richard Ranieri to Board of Directors Monrovia, Calif.
Xencor Appoints Richard Ranieri to Board of Directors Monrovia, Calif. December 19, 2017 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and
Read more →XNCRXencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update Announced Final Results from Phase 2 Trial of XmAb 5871 in IgG4-Related Disease (IgG4-RD); Plan to Initiate Phase 3 Trial in 2H18
Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update Announced Final Results from Phase 2 Trial of XmAb 5871 in IgG4-Related Disease (IgG4-RD); Plan to Initiate Phase 3 Trial in 2H18 Phase 1b Data from Subcutaneous Administration Trial of Xm
Read more →XNCRXencor Reports Second Quarter 2017 Financial Results Management to Host Conference Call Today at 4:30 p.m.
Xencor Reports Second Quarter 2017 Financial Results Management to Host Conference Call Today at 4:30 p.m. ET MONROVIA, Calif., August 7, 2017 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of
Read more →XNCRSECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this Amendment ) is made and effective as of
SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this Amendment ) is made and effective as of July 5, 2017 (the Effective Date ) by and between 111 LEMON INVESTORS LLC, a California limited liability company ( Landlord ) and XENCOR, INC., a Delaware corporation ( Tenant
Read more →XNCROFFICE LEASE by and between PRII HIGH BLUFFS LLC, a Delaware limited liability company, and COLLINS CORPORATE CENTER PARTNERS, LLC, a Delaware limited liability company, as tenants in common ( Landlord ) and XENCOR, INC.
PRII HIGH BLUFFS LLC, a Delaware limited liability company, COLLINS CORPORATE CENTER PARTNERS, LLC, a Delaware limited liability company, as tenants in common a Delaware corporation THIS OFFICE LEASE ( Lease ) is made between PRII HIGH BLUFFS LLC, a Delaware limited liabilit
Read more →XNCRXencor, Inc. 1Q17 Earnings Conference Call Script Tuesday
1Q17 Earnings Conference Call Script Tuesday, May 9, 2017 4:30pm ET (1:30pm PT) Operator Remarks and Welcome: Good afternoon and welcome to the Xencor first quarter 2017 financial results conference call. At this time, all participants are in a listen-only mode. Following the
Read more →XNCRXencor Reports First Quarter 2017 Financial Results Phase 1 Data from Subcutaneous Administration Trial of XmAb 5871 Support Biweekly Dosing Management to Host Conference Call Today at 4:30 p.m.
Xencor Reports First Quarter 2017 Financial Results Phase 1 Data from Subcutaneous Administration Trial of XmAb 5871 Support Biweekly Dosing Management to Host Conference Call Today at 4:30 p.m. ET MONROVIA, Calif., May 9, 2017 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage bio
Read more →XNCRXencor Appoints Kevin Gorman, Ph.D., to its Board of Directors Monrovia, Calif.
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors Monrovia, Calif. April 17, 2017 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that K
Read more →XNCRXencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders Monrovia, Calif.
Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders Monrovia, Calif. March 6, 2017 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company develo
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2016 Financial Results Reported promising preliminary data from Phase 2 study of XmAb 5871 in IgG4-Related Disease (IgG4-RD) Announced strategic collaboration with Novartis for
Xencor Reports Fourth Quarter and Full Year 2016 Financial Results Reported promising preliminary data from Phase 2 study of XmAb 5871 in IgG4-Related Disease (IgG4-RD) Announced strategic collaboration with Novartis for bispecific antibodies Robust cash position supports oper
Read more →XNCRPreliminary Data from On-going IgG4-RD Phase 2 Trial Patients Shows Encouraging Early Responses in 82% of Preliminary data indicates XmAb5871 in active IgG4-RD was well tolerated. C o m p l e t e d 3 0 Treatment response
Preliminary Data from On-going IgG4-RD Phase 2 Trial Patients Shows Encouraging Early Responses in 82% of Preliminary data indicates XmAb5871 in active IgG4-RD was well tolerated. C o m p l e t e d 3 0 Treatment responses (decrease of IgG4-RD RI of 2) observed in 9 of 11 patients
Read more →XNCRXencor Reports Third Quarter 2016 Financial Results
Xencor Reports Third Quarter 2016 Financial Results MONROVIA, Calif., November 2, 2016 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and c
Read more →XNCREQUITY DISTRIBUTION PROGRAM $40,000,000 XENCOR, INC. Common Stock
EQUITY DISTRIBUTION PROGRAM EQUITY DISTRIBUTION AGREEMENT Minneapolis, Minnesota 55402 Ladies and Gentlemen: Xencor, Inc., a company organized under the laws of the State of Delaware (the Company ), proposes to issue and sell from time to time through Piper Jaffray & Co. (the
Read more →XNCRXencor Reports Second Quarter 2016 Financial Results - Expanded bispecific oncology pipeline through strategic collaboration with Novartis and naming of two new drug candidates Xencor management to host conference call t
Xencor Reports Second Quarter 2016 Financial Results - Expanded bispecific oncology pipeline through strategic collaboration with Novartis and naming of two new drug candidates Xencor management to host conference call today at 4:30 p.m. ET Monrovia, CA August 2, 2016 Xencor,
Read more →XNCRXencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676 - Novartis to receive ex U.S. Rights to XmAb14045 and XmAb13676 - Xencor retains all U.S. rights to XmAb14045 and XmAb
Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676 - Novartis to receive ex U.S. Rights to XmAb14045 and XmAb13676 - Xencor retains all U.S. rights to XmAb14045 and XmAb13676 - Collaboration also includes XmAb Bispecific Techn
Read more →XNCRXencor Reports First Quarter 2016 Financial Results Monrovia, CA
Xencor Reports First Quarter 2016 Financial Results Monrovia, CA May 2, 2016 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, tod
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2015 Financial Results Monrovia, Calif.
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results Monrovia, Calif. March 7, 2016 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic dis
Read more →XNCRXencor Announces Change to Board of Directors
Xencor Announces Change to Board of Directors MONROVIA, Calif., January 11, 2016 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer
Read more →XNCRXencor Reports Third Quarter 2015 Financial Results and Pipeline Update Monrovia, Calif.
Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update Monrovia, Calif. November 3, 2015 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biotechnology company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic
Read more →XNCRAMGEN AND XENCOR ANNOUNCE STRATEGIC COLLABORATION IN CANCER IMMUNOTHERAPY AND INFLAMMATION Combines Amgen s Proprietary Antibodies and Xencor s XmAb Bispecific Antibody Platform to Develop New Therapeutic Candidates Incl
AMGEN AND XENCOR ANNOUNCE STRATEGIC COLLABORATION IN CANCER IMMUNOTHERAPY AND INFLAMMATION Combines Amgen s Proprietary Antibodies and Xencor s XmAb Bispecific Antibody Platform to Develop New Therapeutic Candidates Includes Xencor s Pre-Clinical CD38 Bispecific T Cell Engager
Read more →XNCRXencor Reports Second Quarter 2015 Financial and Operating Results
Xencor Reports Second Quarter 2015 Financial and Operating Results MONROVIA, Calif. August 4, 2015 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic di
Read more →XNCRXencor Reports First Quarter 2015 Financial and Operating Results Monrovia, Calif.
Xencor Reports First Quarter 2015 Financial and Operating Results Monrovia, Calif. May 4, 2015 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic disease
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2014 Financial Results Conference call to be held today at 4:30 p.m. ET Monrovia, Calif.
Xencor Reports Fourth Quarter and Full Year 2014 Financial Results Conference call to be held today at 4:30 p.m. ET Monrovia, Calif. February 19, 2015 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the trea
Read more →XNCRLEASE between BF MONROVIA, LLC a California limited liability company as Landlord and Xencor, Inc. a California corporation as Tenant
a California limited liability company a California corporation Page 1. Parties and Prior Lease 1 1.1 Current Lease 1 1.2 Prior Lease 1 2. Premises 1 2.1 Leased Premises 1 2.2 Common Areas 1 2.3 Telephone Room and Roof 1 2.4 Parking 2 2.5 Right of First Offer to Lease
Read more →XNCRXencor Reports Third Quarter 2014 Financial Results Conference call today at 4:30 p.m. EST Monrovia, Calif.
Xencor Reports Third Quarter 2014 Financial Results Conference call today at 4:30 p.m. EST Monrovia, Calif. November 10, 2014 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disea
Read more →XNCRXencor Reports Second Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT Monrovia, Calif.
Xencor Reports Second Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT Monrovia, Calif. July 31, 2014 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases
Read more →XNCRXencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer MONROVIA, Calif., July 15, 2014 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of au
Read more →XNCRXencor Reports First Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT Monrovia, Calif.
Xencor Reports First Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT Monrovia, Calif. May 14, 2014 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases,
Read more →XNCRXencor Reports Fourth Quarter and Full Year 2013 Financial Results Conference call to be held at 4:30 p.m. EDT Monrovia, CA
Xencor Reports Fourth Quarter and Full Year 2013 Financial Results Conference call to be held at 4:30 p.m. EDT Monrovia, CA March 19, 2014 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of aut
Read more →Competitive Position
How XNCR ranks across every disease it competes inCompetitive Position is a premium feature
See how XNCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial